Please login to the form below

Not currently logged in
Email:
Password:

Chase

This page shows the latest Chase news and features for those working in and with pharma, biotech and healthcare.

Gilead, Galapagos JAK inhibitor clears phase II test

Gilead, Galapagos JAK inhibitor clears phase II test

A mid-stage trial of Gilead and Galapagos’JAK1 inhibitor filgotinib has set up a phase III programme for the drug in ankylosing spondylitis as it chases down two already-marketed

Latest news

More from news
Approximately 1 fully matching, plus 50 partially matching documents found.

Latest Intelligence

  • Leo has its eyes on the prize Leo has its eyes on the prize

    The Leo surge will include gene therapy and the flexibility to push its R&D investment up to 25% of sales as it chases the ambitious strategy through to 2025.

  • Proving real-world value Proving real-world value

    Claims to be patient-centric are often contradicted by strategies that focus purely on the numbers and chase quarterly targets as a barometer of success.

  • Deal Watch November 2016 Deal Watch November 2016

    of $125m and additional regulatory and sales milestones related to Chase's phase III ready lead compound, CPC-201 for Alzheimer's, and certain backup compounds. ... equity investment, 2 year collaboration. 145. Chase Pharmaceuticals/ Allergan. fixed dose

  • Interview: Georg Toufar, Mundipharma Interview: Georg Toufar, Mundipharma

    Big pharma still chases 'new',” says Toufar. “ In some instances, such as in some orphan drugs this is amazing, but for 75 per cent of opportunities, it's not.

  • Pharma deals during August 2013 Pharma deals during August 2013

    Amidst the frenzied speculation, however, Onyx' share value jumped more than 50 per cent, inevitably discouraging would-be bidders from joining the chase.

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

  • GW Pharmaceuticals promotes Adam George to MD GW Pharmaceuticals promotes Adam George to MD

    Giacobello, meanwhile, has 25 years experience in finance and operations, most recently as CFO for Chase Pharmaceuticals until its acquisition last year by Allergan.

  • Chase adds former Allergan execs to leadership team Chase adds former Allergan execs to leadership team

    Chase adds former Allergan execs to leadership team. Scott Giacobello and Gary Charbonneau join. ... Charbonneau joins Chase with over 25 years of experience in regulatory, quality and research and development operations.

  • Alan Kidd moves from GSK to Chase Alan Kidd moves from GSK to Chase

    Alan Kidd moves from GSK to Chase. Takes up role as business development manager. ... In his new role within Chase's business development team Kidd will be responsible for enhancing and extending its contract sales and services offering.

  • Chase Pharmaceuticals appoints former Allergan president Chase Pharmaceuticals appoints former Allergan president

    Chase Pharmaceuticals appoints former Allergan president. Douglas Ingram joins as chief executive officer. ... Ingram said: “ I am privileged to lead Chase Pharmaceuticals as we execute an elegant approach to the development of new Alzheimer's

More from appointments
Approximately 3 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Strategy - It's All About Choices

    If you chase two rabbits, both will escape’: if ever there was a saying which demonstrated what is at the heart of a great strategy, then this is it. ... In my experience too many pharma companies build strategies geared to chase everything; leaving

  • Developing your patient-centric strategy

    Much of our historic effort has been led by the virus – a chase of science.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics